A recently FDA-approved therapy for GA, pegcetacoplan (SYFOVRETM, Apellis), specifically inhibits complement C3 and has demonstrated delays in the advancement of dry AMD and decelerating the growth of GA lesions [11,13,14]. This evidence concerns the gene C3 and dry age related macular degeneration.